SCHEMBL4154285

SCHEMBL4154285

CCNc1nc(C)c(-c2ccnc(N)n2)s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 7/20 0.62
▸ CDK4 P11802 6/20 0.62
▸ CCNE1 P24864 1/20 0.62
▸ AURKB Q96GD4 5/20 0.55
▸ AURKA O14965 5/20 0.55
▸ CDK9 P50750 5/20 0.55
▸ CDK7 P50613 4/20 0.55
▸ CDK1 P06493 3/20 0.55
▸ WEE1 P30291 2/20 0.51
▸ FLT3 P36888 2/20 0.51
▸ ALK Q9UM73 2/20 0.51
▸ ROCK1 Q13464 10/20 0.48
▸ MAP4K4 O95819 2/20 0.48
▸ PRKACA P17612 2/20 0.48
▸ MAPK9 P45984 2/20 0.48
▸ CSNK1A1 P48729 2/20 0.48
▸ CLK2 P49760 2/20 0.48
▸ NEK2 P51955 2/20 0.48
▸ LIMK1 P53667 2/20 0.48
▸ MAP4K2 Q12851 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169064 0.84 CDK2 (0.68) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL22684842 0.77 CDK4 (0.76) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL4314069 0.77 CDK2 (1.00) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL18453974 0.76 CDK4 (0.63) CDK2CDK4CCNE1AURKBCDK9
SCHEMBL4164820 0.76 CDK2 (0.46) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL4800409 0.75 CDK2 (0.71) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL6156585 0.75 CDK2 (0.71) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL22684839 0.75 CDK2 (0.62) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL28510431 0.75 CDK4 (0.62) CDK2CDK4CCNE1AURKBAURKA
SCHEMBL5164202 0.74 CDK2 (0.47) CDK2CDK4CCNE1AURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 — — US claimed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 — — EP claimed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 — — WO claimed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 — — US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 — — US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 — — US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 — — EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 CDK2 1/4885CDK4 2/4885CCNE1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback